Tags : Illumina


Insights+: Key Deals of JP Morgan Healthcare Conference 2021

This year J.P. Morgan 39th Annual Healthcare Conference was conducted virtually and we witnessed multiple announcements from numerous Biopharma companies An analysis of events and catalysts that were announced at the conference during these days are included in the report. Most of the deals occurred in the first two days of the conference Our PharmaShots […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshot (Sept 21-25, 2020)

Philips Launches QuickClear Mechanical Thrombectomy System for Blood Clot Removal Published: Sept 25,2020 | Tags: Philips, Launches, QuickClear Mechanical Thrombectomy System, Blood Clot Removal 2. BMS Reports Results of Opdivo (nivolumab) in P-III CheckMate -274 Study for Patients with High-Risk Muscle-Invasive Urothelial Carcinoma Published: Sept 25,2020 | Tags: BMS, Reports, Results, Opdivo, (nivolumab), P-III, CheckMate […]Read More


Illumina to Acquire GRAIL for ~$8B

Shots: Illumina to acquire GRAIL in cash & stock transaction for $8B including ~$3.5B in cash and $4.5B in shares of Illumina common stock. Illumina founded GRAIL in 2016 and later spun out it to develop state-of-the-art data science, ML and create the atlas of cancer signals in the blood, enabling multi-cancer early detection tests […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshot (January 13-17, 2020)

1. Arena’s APD418 Receives FDA’s Fast Track Designation to Treat Patients with Decompensated Heart Failure Published: Jan 17, 2020 | Tags: Arena, APD418, Receives, FDA, Fast Track Designation, Treat, Patients, Decompensated Heart 2. Charles River Collaborates with Fios Genomics for Bioinformatics-Driven Drug Discovery and Safety Assessment Published: Jan 16, 2020 | Tags: Charles River, Collaborates, Fios Genomics, […]Read More


Roche Collaborates with Illumina to Expand the Adoption of NGS

Shots: Roche signs a 15yrs. non-exclusive agreement with Illumina, allowing patients to access next-generation sequencing (NGS) based testing in oncology Roche to get right to develop & commercialize AVENIO IVD tests for both tissue and blood to be used on Illumina’s NextSeq 550Dx System while Illumina will continue to commercialize its NextSeq 550Dx Systems and […]Read More


Illumina Acquires Pacific Biosciences for ~$1.2B with its Sequel SMRT

Shots: Pacific to get $8.00/share making $1.2B as total deal value in cash, with its expected closure in Q2’19 The acquisition is a focus to combine Pacific’s Sequel SMRT Technology for expansion of its biological discovery platform by bringing short- and long-read sequencing technologies together Sequel SMRT (Single-Molecule Real-Time) Technology is an automated system with […]Read More